1083326-75-3

基本信息
N- [2-甲氧基-5-(4,4,5,5-四甲基-1,3,2-二氧硼杂环戊烷-2-基)吡啶-3-基]甲磺酰胺
N-(2-甲氧基-5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)吡啶-3-基)甲烷磺酰胺
N-[2-(甲氧基)-5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-3-吡啶基]甲烷磺酰胺
N-(2-Methoxy-5-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)MethanesulfonaMide
N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE
N-[2-(Methyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-pyridinyl]methanesulfonamide
物理化学性质
制备方法

1083327-58-5

73183-34-3
![N-[2-METHOXY-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3-PYRIDINYL]-METHANESULFONAMIDE](/CAS/GIF/1083326-75-3.gif)
1083326-75-3
一般步骤:将N-(5-溴-2-甲氧基吡啶-3-基)甲磺酰胺(3.35 g,11.9 mmol)和联硼酸频那醇酯(4.24 g,16.7 mmol)悬浮于甲苯(100 mL)中,脱气并用氮气置换三次。随后加入三(二亚苄基丙酮)二钯(616 mg,0.595 mmol)和三苯基膦(243 mg,0.892 mmol)。将混合物加热至45℃并搅拌45分钟,然后加入乙酸钾(3.74 g,23.8 mmol)。将反应混合物加热至回流并继续搅拌3小时。反应完成后,冷却至室温,用乙酸乙酯(100 mL)稀释,并通过硅藻土过滤。滤液依次用水(70 mL×3)和饱和盐水(100 mL)洗涤,无水硫酸钠干燥,减压浓缩。残余物通过硅胶柱色谱(石油醚/乙酸乙酯,体积比=2/1)纯化,得到N-(2-甲氧基-5-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)吡啶-3-基)甲烷磺酰胺,为白色固体(2.90 g,74%)。质谱(ESI,阳离子模式)m/z:328.9 [M + H]+;1H NMR(600 MHz,CDCl3):δ 8.32(d,J=1.4 Hz,1H),8.06(d,J=1.3 Hz,1H),6.66(br s,1H),4.05(s,3H),3.02(s,3H),1.33(s,12H)。
参考文献:
[1] Organic Process Research and Development, 2018, vol. 22, # 3, p. 368 - 376
[2] Patent: US2014/134133, 2014, A1. Location in patent: Paragraph 0441
[3] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 3, p. 637 - 646
[4] Journal of Medicinal Chemistry, 2018, vol. 61, # 14, p. 6087 - 6109
[5] European Journal of Medicinal Chemistry, 2018, vol. 146, p. 460 - 470